Choose from 31 PDX models covering colorectal, endometrial, esophagael, gastric, melanoma, NSCLC and ovarian cancer, to advance your preclinical compounds.
Enrollment deadline: Enrolling until March 27th, 2026
Request more information on our In Vivo Screen for APC/β-Catenin Dysregulation
Test your small molecules, biologics, ADCs, and rational combinations targeting the APC/β‑catenin pathway.
Aberrations in the APC/β‑catenin (Wnt) pathway drive tumor initiation, progression, and therapeutic resistance across multiple solid tumors. Champions’ upcoming multi‑indication screen lets your team quickly pressure‑test mechanisms acting on this pathway, de‑risking go/no‑go decisions and informing indication strategy with in vivo evidence generated in clinically relevant PDX models.
-
Purpose‑built for APC/β‑catenin dysregulationThe panel is enriched for tumors with APC/CTNNB1/AXIN1 alterations or pathway activation, enabling mechanism‑aligned testing and biomarker discovery
-
High translational valueAcross large, independent comparisons of PDX responses vs. subsequent patient outcomes, Champions PDX have shown 85% PPV and 91% NPV, supporting high translational confidence.
-
Seven tumor typesFeaturing 15 colorectal, 4 NSCLC, 3 esophageal, 3 melanoma, 2 endometrial, 2 gastric and 2 ovarian cancer models, with mutations such as KRAS, TP53, PIK3CA and more.
-
Collaborative Standard-of-Care armComparator context via an optional standard‑of‑care cost‑share arm, facilitating internal and external benchmarking.
-
Optional multi-omicsBy request, you can leverage multi‑omics (RNA‑seq, WES) and IHC panels (e.g., β‑catenin localization), through our established profiling workflows across our preclinical platforms.
-
Multiple efficacy readoutsTumor volume kinetics, TGI, response categorization plus tolerability and body‑weight monitoring, delivered in publication‑ready figures and raw data files.
Model Overview
Choose from 31 PDX models covering colorectal, endometrial,
esophagael, gastric, melanoma, NSCLC and ovarian cancer
|
Model
|
Tumor type
|
Mutations
|
Expression
|
Suggested SoCs
|
|---|---|---|---|---|
|
CTG-0081
|
Colorectal
|
TP53
|
None
|
FOLFIRI or FOLFOX
|
|
CTG-0148
|
Gastric
|
PIK3CA
|
MLH-low
|
Alpelisib
|
|
CTG-0387
|
Colorectal
|
KRAS G12C
|
None
|
Daraxonrasib; Sotorasib
|
|
CTG-0497
|
Colorectal
|
PIK3CA
|
CDK4-high
|
Alpelisib
|
|
CTG-0654
|
Colorectal
|
KRAS G12D
|
PTEN-low
|
Daraxonrasib; Sotorasib; Alpelisib
|
|
CTG-0661
|
Colorectal
|
KRAS G12S
|
CDK4-high
|
Daraxonrasib; Sotorasib; Palbo
|
|
CTG-0676
|
Esophageal
|
ERBB2
|
None
|
Trastuzumab deruxtecan; Trastuzumab emtansine
|
|
CTG-0812
|
Colorectal
|
None
|
CDK4-high; ERBB3-high
|
Palbociclib
|
|
CTG-0835
|
Colorectal
|
KRAS G13D; PIK3CA
|
None
|
Daraxonrasib; Sotorasib; Alpelisib
|
|
CTG-0951
|
Colorectal
|
KRAS G13D; BRCA2
|
AKT2-high
|
Daraxonrasib; Sotorasib
|
|
CTG-1170
|
Colorectal
|
KRAS G12V
|
None
|
Daraxonrasib; Sotorasib; Trastuzumab deruxtecan
|
|
CTG-1280
|
Endometrial
|
PTEN
|
CDK4-high; MLH1-low
|
Datopotamab; Sacituzumab; Alpelisib; Palbociclib
|
|
CTG-1423
|
Ovarian
|
PIK3CA
|
FGFR1-high
|
Alpelisib; Capivasertib
|
|
CTG-1471
|
Melanoma
|
None
|
CDK4-high; CCND1-high
|
Palbociclib; Binimetinib
|
|
CTG-1472
|
Colorectal
|
KRAS G12V; PIK3CA
|
None
|
Daraxonrasib; Sotorasib
|
|
CTG-1553
|
Colorectal
|
KRAS G12V
|
CDK4-high
|
Daraxonrasib; Sotorasib
|
|
CTG-1677
|
Ovarian
|
BRAF; PTEN
|
None
|
Vemurafenib; Palbociclib
|
|
CTG-1741
|
Esophageal
|
None
|
CCND1-high
|
Palbociclib
|
|
CTG-1762
|
NSCLC
|
None
|
FGFR1-high; CDK4-high
|
Trametinib; Avutometinib; Palbociclib
|
|
CTG-1876
|
Esophageal
|
TP53
|
None
|
Zongertinib; Zanidatamab; Disitamab
|
|
CTG-1951
|
Colorectal
|
KRAS G12D
|
None
|
Daraxonrasib; Sotorasib
|
|
CTG-2164
|
Colorectal
|
KRAS G12V; PIK3CA
|
CDK4-high
|
Daraxonrasib; Sotorasib
|
|
CTG-2556
|
NSCLC
|
PTEN
|
CDK4-high
|
Alpelisib; Trametinib; Avutometinib
|
|
CTG-2647
|
Endometrial
|
AKT1
|
None
|
Datopotamab; Sacituzumab; Camizestrant
|
|
CTG-2768
|
Melanoma
|
BRAF
|
CDK4-high; CCND1-high
|
Vemurafenib; Palbociclib
|
|
CTG-2776
|
NSCLC
|
None
|
None
|
Palbociclib; Cis/Gem
|
|
CTG-3032
|
Gastric
|
BRCA2; PIK3CA
|
CDK4-high
|
Alpelisib
|
|
CTG-3063
|
Melanoma
|
BRAF
|
CDK4-high; CCND1-high; ERBB3-high
|
Vemurafenib; Palbociclib
|
|
CTG-3121
|
NSCLC
|
RB1
|
CDK4-high
|
Palbociclib; Trametinib; Avutometinib
|
|
CTG-3494
|
Colorectal
|
None
|
CCND1-high; MAPK3-high
|
Palbociclib; Trametinib; Avutometinib
|
|
CTG-3631
|
Colorectal
|
KRAS G12R
|
CDK4-high; ERBB3-high
|
Daraxonrasib; Sotorasib
|